Zoetis (ZTS) Stock Price
Zoetis Price
Zoetis (ZTS) Stock | ISIN US98978V1035 | WKN A1KBYX. The current Zoetis stock price is 82.56 USD (2026). Revenue is 10 B USD. Net income is 3.14 B USD. The P/E ratio is 11.66. Market capitalization is 36.64 B USD. Zoetis operates in the Health sector.
Zoetis stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Zoetis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Zoetis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Zoetis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Zoetis Price |
|---|
Zoetis Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Zoetis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Zoetis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Zoetis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Zoetis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Zoetis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Zoetis stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis business model & stock analysis
Zoetis SWOT Analysis
Strengths
Zoetis Inc is a leading global animal health company, enjoying a strong market presence and brand reputation.
The company boasts a diverse portfolio of animal health products, including vaccines, diagnostics, and medicines.
Zoetis Inc has a highly skilled and experienced workforce, enabling efficient research and development processes.
Weaknesses
Zoetis Inc heavily relies on a few major customers, which poses a potential risk to its revenue if any customer reduces or discontinues their purchases.
The company faces high regulatory requirements and strict compliance standards in the animal health industry, which may increase operational costs.
Zoetis Inc has limited geographic diversification, with a significant portion of its revenue coming from sales in North America.
Opportunities
The growing global concern for animal welfare and the increasing demand for quality healthcare products provide an opportunity for Zoetis Inc to expand its product offerings.
The rise in pet ownership and the growing pet healthcare market offer potential for the company's growth.
The advancement of technology, such as digital platforms and data analytics, can enable Zoetis Inc to enhance its research capabilities and develop innovative solutions.
Threats
Zoetis Inc faces intense competition from both multinational corporations and local players in the animal health industry.
Changes in government regulations and policies can impact market access, pricing, and product approvals.
Economic downturns and fluctuations in currency exchange rates can affect the purchasing power and demand for animal health products.
Zoetis Segments
Zoetis Revenue by Segment (1/6)
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Revenue by Segment (2/6)
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Revenue by Segment (3/6)
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Revenue by Segment (4/6)
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Revenue by Segment (5/6)
3 Years
5 Years
10 Years
Max
Details
Zoetis Revenue by Segment (6/6)
3 Years
5 Years
10 Years
Max
Details
Zoetis Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Zoetis Eulerpool Fair Value
Zoetis historical P/E ratio, EBIT multiple, and P/S ratio
Zoetis annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Zoetis shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Dividend History
14 years of dividend payments · 12 consecutive increases
Zoetis dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Zoetis Earnings Estimates
Zoetis Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/7/2026 | 1.63USD | 2.33 BUSD | 2026 Q1 |
| 2/12/2026 | 1.42USD | 2.38 BUSD | 2025 Q4 |
| 5/2/2024 | 1.42USD | 2.22 BUSD | 2024 Q1 |
| 2/12/2024 | 1.33USD | 2.22 BUSD | 2023 Q4 |
| 8/2/2023 | 1.36USD | 2.21 BUSD | 2023 Q2 |
| 5/3/2023 | 1.37USD | 2.08 BUSD | 2023 Q1 |
| 2/13/2023 | 1.16USD | 2.08 BUSD | 2022 Q4 |
| 11/3/2022 | 1.25USD | 2.11 BUSD | 2022 Q3 |
| 8/4/2022 | 1.23USD | 2.07 BUSD | 2022 Q2 |
| 5/5/2022 | 1.25USD | 2.01 BUSD | 2022 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Zoetis stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Zoetis Executives and Management Board
Ms. Kristin Peck
(53)Chief Executive Officer, Director · since 2012
Mr. Wetteny Joseph
(52)Chief Financial Officer, Executive Vice President
Mr. Jamie Brannan
(52)Executive Vice President, Chief Commercial Officer
Ms. Roxanne Lagano
(60)Executive Vice President, General Counsel, Corporate Secretary
Mr. Michael Mccallister
(72)Non-Executive Independent Chairman of the Board
Zoetis Supply Chain
Frequently asked questions about Zoetis
Zoetis Inc. operates as a leading animal health company globally. The business model of Zoetis Inc. revolves around discovering, developing, manufacturing, and marketing a diverse range of animal health products and vaccines. With a focus on improving the health and well-being of animals, Zoetis aims to provide innovative solutions that enhance the health, productivity, and performance of livestock and companion animals. By offering a wide portfolio of products and services, Zoetis caters to the needs of veterinarians, livestock producers, and pet owners, thereby contributing to the overall welfare and sustainability of the animal health industry.
Zoetis stock
Zoetis Peer Group
Zoetis Ticker
Zoetis FIGI
All fundamentals and in-depth analysis of Zoetis
Our stock analysis for Zoetis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zoetis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.